Literature DB >> 12480698

Degenerate specificity of HTLV-1-specific CD8+ T cells during viral replication in patients with HTLV-1-associated myelopathy (HAM/TSP).

Ryuji Kubota1, Yoshitaka Furukawa, Shuji Izumo, Koichiro Usuku, Mitsuhiro Osame.   

Abstract

Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an inflammatory neurologic disease caused by HTLV-1 infection, in which HTLV-1-infected CD4(+) T cells and HTLV-1-specific CD8(+) T cells may play a role in the disease pathogenesis. Patients with HAM/TSP have high proviral loads despite vigorous virus-specific CD8(+) T-cell responses; however, it is unknown whether the T cells are efficient in eliminating the virus in vivo. To define the dynamics of HTLV-1-specific CD8(+) T-cell responses, we investigated longitudinal alterations in HTLV-1 proviral load, amino acid changes in an immunodominant viral epitope, frequency of HTLV-1-specific T cells, and degeneracy of T-cell recognition in patients with HAM/TSP. We showed that the frequency and the degeneracy of the HTLV-1-specific CD8(+) T cells correlated well with proviral load in the longitudinal study. The proviral load was much higher in a patient with low degeneracy of HTLV-1-specific T cells compared to that in a patient with comparable frequency but higher degeneracy of the T cells. Furthermore, in a larger number of patients divided into 2 groups by the proviral load, those with high proviral load had lower degeneracy of T-cell recognition than those with low proviral load. Sequencing analysis revealed that epitope mutations were remarkably increased in a patient when the frequency and the degeneracy were at the lowest. These data suggest that HTLV-1-specific CD8(+) T cells with degenerate specificity are increased during viral replication and control the viral infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480698     DOI: 10.1182/blood-2002-08-2477

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding.

Authors:  Won-Kyung Cho; Moon Kyoo Jang; Keven Huang; Cynthia A Pise-Masison; John N Brady
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1.

Authors:  Risaku Fukumoto; Miroslav Dundr; Christophe Nicot; Anthony Adams; Valerio W Valeri; Lawrence E Samelson; Genoveffa Franchini
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

Review 3.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 4.  The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection.

Authors:  Shin-Ichi Yokota; Tamaki Okabayashi; Nobuhiro Fujii
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

5.  Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.

Authors:  Taraneh Rajaei; Hamid Farajifard; Seyed Abdolrahim Rezaee; Mahmoud Reza Azarpazhooh; Mahmoud Mahmoudi; Narges Valizadeh; Houshang Rafatpanah
Journal:  Med Microbiol Immunol       Date:  2018-10-20       Impact factor: 3.402

6.  Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Eiji Matsuura; Ryuji Kubota; Yuetsu Tanaka; Hiroshi Takashima; Shuji Izumo
Journal:  J Neuropathol Exp Neurol       Date:  2015-01       Impact factor: 3.685

Review 7.  T cell receptor repertoire analysis in HTLV-1-associated diseases.

Authors:  Annaliese Clauze; Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

Review 8.  Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Kate Barmak; Edward W Harhaj; Brian Wigdahl
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 3.739

Review 9.  Pathogenesis of HTLV-1 infection and progression biomarkers: An overview.

Authors:  Carlos Brites; Maria Fernanda Grassi; Juarez Antônio Simões Quaresma; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Braz J Infect Dis       Date:  2021-07-10       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.